Wegovy
Semaglutide at the higher, weight-loss-specific dose
Wegovy is semaglutide dosed up to 2.4mg weekly, Health Canada-approved since 2021 specifically for chronic weight management in adults with obesity or overweight with weight-related conditions. It's the only semaglutide product with an on-label weight-loss indication in Canada, which matters for some insurance approval processes.
Pros
- ✓On-label for weight management — not an off-label use like Ozempic for weight loss
- ✓Highest average weight loss of the two options: 15–22% of body weight at 2.4mg
- ✓Purpose-built dose titration schedule for weight management specifically
- ✓Some private insurers require on-label indication for any coverage consideration
Cons
- ✗$300–400+/month out of pocket — more expensive than generic semaglutide
- ✗Limited provincial drug plan coverage even though it's on-label for weight loss
- ✗No generic version — semaglutide generics currently only match the lower Ozempic-equivalent doses
- ✗Less pharmacy stock consistency than Ozempic/generic semaglutide
Best for: Canadians who want the maximum semaglutide dose specifically approved for weight loss, and whose insurer requires an on-label prescription for any possible reimbursement consideration.
Cost: $300–400/month self-pay; limited coverage even under private plans.
Canada availability: Available at major pharmacy chains and telehealth providers across Canada, though less consistently stocked than Ozempic.